Eltrombopag

Generic Name
Eltrombopag
Brand Names
Promacta, Revolade
Drug Type
Small Molecule
Chemical Formula
C25H22N4O4
CAS Number
496775-61-2
Unique Ingredient Identifier
S56D65XJ9G
Background

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication

Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions
Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
Associated Therapies
First-line Therapy
Clinical Trials
Related News

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Phase 3
Completed
Conditions
Hepatitis C, Chronic
First Posted Date
2007-08-15
Last Posted Date
2013-11-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
687
Registration Number
NCT00516321
Locations
🇬🇧

GSK Investigational Site, Plymouth, United Kingdom

Eltrombopag Taste Testing in Healthy Adult Volunteers

First Posted Date
2007-06-19
Last Posted Date
2012-03-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
12
Registration Number
NCT00487968
Locations
🇺🇸

GSK Investigational Site, Overland Park, Kansas, United States

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Phase 1
Completed
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Drug: eltrombopag
First Posted Date
2007-03-05
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
29
Registration Number
NCT00442871
Locations
🇺🇸

GSK Investigational Site, Saint Paul, Minnesota, United States

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Phase 2
Completed
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Drug: eltrombopag
First Posted Date
2007-01-18
Last Posted Date
2013-07-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
66
Registration Number
NCT00424177
Locations
🇷🇺

GSK Investigational Site, Moscow, Russian Federation

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

First Posted Date
2006-08-31
Last Posted Date
2017-04-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
197
Registration Number
NCT00370331
Locations
🇻🇳

GSK Investigational Site, Ho Chi Minh, Vietnam

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Phase 1
Completed
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Drug: eltrombopag
First Posted Date
2006-08-02
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
33
Registration Number
NCT00359463
Locations
🇳🇿

GSK Investigational Site, Christchurch, New Zealand

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

Phase 1
Completed
Conditions
Thrombocytopaenia
Interventions
Drug: eltrombopag
First Posted Date
2006-08-01
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
18
Registration Number
NCT00358540
Locations
🇺🇸

GSK Investigational Site, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy